


## Dehydroandrographolide succinate potassium sodium salt

## Chemical Properties

CAS No. : 863319-40-8  
 Formula: C<sub>28</sub>H<sub>34</sub>KNaO<sub>10</sub>  
 Molecular Weight: 592.65  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Dehydroandrographolide succinate potassium sodium salt is a natural product from <i>Andrographis paniculata</i> that exerts anti-inflammatory and immunomodulatory effects by inhibiting the production of inflammatory mediators (NO, TNF- $\alpha$ ) and regulating immune responses. Dehydroandrographolide succinate exhibits antithrombotic effects. Dehydroandrographolide succinate can be used in research on viral pneumonia and viral upper respiratory tract infections.
Targets(IC50)	Others, Influenza Virus
In vitro	<p>Methods: Whole blood was collected from healthy volunteers. Dehydroandrographolide succinate potassium sodium salt was added to achieve final concentrations of 0.5, 1.0, and 1.5 mg/mL, and the samples were incubated at 37°C for 2 hours. A fully automated coagulation analyzer was used to measure prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fg), thrombin time (TT), and antithrombin III (AT-III) using an automated coagulation analyzer. [1]</p> <p>Results: Dehydroandrographolide succinate potassium sodium salt concentration-dependently shortened APTT and TT, increased fibrinogen (Fg) levels and antithrombin III (AT-III) activity; high-dose DAS significantly shortened PT and significantly enhanced anticoagulant capacity.</p>
In vivo	<p>Methods: Male SD rats were administered intraperitoneal injections of Dehydroandrographolide succinate potassium sodium salt at doses of 200, 400, and 600 mg/kg once daily for 3 consecutive days.</p> <p>Results: Dehydroandrographolide succinate potassium sodium salt (400, 600 mg/kg) significantly inhibited platelet aggregation, significantly shortened PT and APTT, and increased fibrinogen (Fg) levels and antithrombin III (AT-III) activity. [1]</p>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.6873 mL	8.4367 mL	16.8734 mL
5 mM	0.3375 mL	1.6873 mL	3.3747 mL
10 mM	0.1687 mL	0.8437 mL	1.6873 mL
50 mM	0.0337 mL	0.1687 mL	0.3375 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Yin B, et al. The antithrombosis effect of dehydroandrographolide succinate: in vitro and in vivo studies. *Pharm Biol.* 2022;60(1):175-184.

Xiaomeng Z, et al. Potassium dehydroandrographolide succinate injection for treatment of infantile pneumonia: a systematic review and Meta-analysis. *J Tradit Chin Med.* 2015 Apr;35(2):125-33.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481